Health Care • Biotechnology: Pharmaceutical Preparations
$1.95 ▼ -0.10
(-4.88%)
MKT CAP: $163.3M • VOL: 533.0K
52W L $2 52W H $7
ROARABLE / RQD
D- • 37/100
PIOTROSKI
2 / 9
CNTN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$20.1M | -$12.4M | -$9.5M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$35.9M | -$12.2M | -$9.3M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$16.1M | -$10.9M | -$7.3M |
| Capital Expenditures (CapEx) | — | — | — |
| Free Cash Flow (FCF) | -$16.1M | -$10.9M | -$7.3M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -4.1% | -45.0% | — |
| Cash & Short-Term Equivalents | $12.0M | $3.6M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $397.9M | $1.3M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CNTN.